Cytokinetics Expands MYQORZO Launch to Europe with Germany Debut

Event summary

  • Cytokinetics launched MYQORZO (aficamten) in Germany, its first European market, on June 1, 2026.
  • The approval follows European Commission clearance in February 2026, based on positive Phase 3 SEQUOIA-HCM trial results.
  • MYQORZO improved exercise capacity by 1.76 mL/kg/min in oHCM patients compared to placebo.
  • The drug is already approved in the U.S. (December 2025) and China for symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
  • Cytokinetics plans additional European launches following the German debut.

The big picture

Cytokinetics' European launch of MYQORZO marks a strategic expansion into a major pharmaceutical market, following successful U.S. and Chinese approvals. The drug's mechanism as a cardiac myosin inhibitor positions it as a key player in treating obstructive hypertrophic cardiomyopathy, a condition affecting approximately 1 in 350 individuals worldwide. The company's ability to replicate its U.S. commercial success in Europe will be critical for its long-term growth.

What we're watching

Market Penetration
How quickly Cytokinetics can expand MYQORZO's availability across other European markets following the German launch.
Regulatory Momentum
Whether the positive European and U.S. approvals will accelerate discussions with other global regulators.
Pipeline Progress
The pace at which Cytokinetics advances aficamten in non-obstructive HCM and pediatric populations.